These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 25881230

  • 21. c-Met Signaling Protects from Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types.
    Drescher HK, Schumacher F, Schenker T, Baues M, Lammers T, Hieronymus T, Trautwein C, Streetz KL, Kroy DC.
    Oxid Med Cell Longev; 2018; 2018():6957497. PubMed ID: 30538805
    [Abstract] [Full Text] [Related]

  • 22. IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet.
    Luo XY, Takahara T, Kawai K, Fujino M, Sugiyama T, Tsuneyama K, Tsukada K, Nakae S, Zhong L, Li XK.
    Am J Physiol Gastrointest Liver Physiol; 2013 Dec; 305(12):G891-9. PubMed ID: 24136786
    [Abstract] [Full Text] [Related]

  • 23. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
    Allen J, Zhang J, Quickel MD, Kennett M, Patterson AD, Hankey-Giblin PA.
    J Proteome Res; 2018 Sep 07; 17(9):3268-3280. PubMed ID: 30091925
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hepatocellular iNOS protects liver from NASH through Nrf2-dependent activation of HO-1.
    Qiao Y, Li X, Zhang X, Xiao F, Zhu Y, Fang Z, Sun J.
    Biochem Biophys Res Commun; 2019 Jun 25; 514(2):372-378. PubMed ID: 31043271
    [Abstract] [Full Text] [Related]

  • 27. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q, Zhou H, Bu Q, Wei S, Li L, Zhou J, Zhou S, Su W, Liu M, Liu Z, Wang M, Lu L.
    J Hepatol; 2022 Aug 25; 77(2):312-325. PubMed ID: 35292349
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ, Yeh MM, Haigh WG, Van Rooyen DM, Brooling J, Heydet D, Nolan CJ, Teoh NC, Farrell GC.
    Obesity (Silver Spring); 2013 Jun 25; 21(6):1189-99. PubMed ID: 23666886
    [Abstract] [Full Text] [Related]

  • 30. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
    Hartimath SV, Boominathan R, Soh V, Cheng P, Deng X, Chong YC, Yong FF, Tan PW, Han W, Robins EG, Goggi JL.
    Contrast Media Mol Imaging; 2019 Jun 25; 2019():6298128. PubMed ID: 31866798
    [Abstract] [Full Text] [Related]

  • 31. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
    Simon Y, Kessler SM, Gemperlein K, Bohle RM, Müller R, Haybaeck J, Kiemer AK.
    World J Gastroenterol; 2014 Dec 21; 20(47):17839-50. PubMed ID: 25548482
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model.
    Fujita K, Nozaki Y, Yoneda M, Wada K, Takahashi H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Maeyama S, Nakajima A.
    Alcohol Clin Exp Res; 2010 Feb 21; 34 Suppl 1():S18-24. PubMed ID: 18986378
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
    Zhang Y, Wu B, Zhang H, Ge X, Ying S, Hu M, Li W, Huang Y, Wang L, Chen C, Shan X, Liang G.
    J Cell Mol Med; 2018 Feb 21; 22(2):936-947. PubMed ID: 29077272
    [Abstract] [Full Text] [Related]

  • 36. Wild ginseng cambial meristematic cells ameliorate hepatic steatosis and mitochondrial dysfunction in high-fat diet-fed mice.
    Lee SB, Cho HI, Jin YW, Lee EK, Ahn JY, Lee SM.
    J Pharm Pharmacol; 2016 Jan 21; 68(1):119-27. PubMed ID: 26806698
    [Abstract] [Full Text] [Related]

  • 37. Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis.
    Saito K, Uebanso T, Maekawa K, Ishikawa M, Taguchi R, Nammo T, Nishimaki-Mogami T, Udagawa H, Fujii M, Shibazaki Y, Yoneyama H, Yasuda K, Saito Y.
    Sci Rep; 2015 Aug 20; 5():12466. PubMed ID: 26289793
    [Abstract] [Full Text] [Related]

  • 38. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH).
    Jindal A, Bruzzì S, Sutti S, Locatelli I, Bozzola C, Paternostro C, Parola M, Albano E.
    Exp Mol Pathol; 2015 Aug 20; 99(1):155-62. PubMed ID: 26112094
    [Abstract] [Full Text] [Related]

  • 39. Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis.
    Yoshimine Y, Uto H, Kumagai K, Mawatari S, Arima S, Ibusuki R, Mera K, Nosaki T, Kanmura S, Numata M, Tamai T, Moriuchi A, Tsubouchi H, Ido A.
    Oncol Rep; 2015 Apr 20; 33(4):1657-66. PubMed ID: 25607821
    [Abstract] [Full Text] [Related]

  • 40. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
    Pan ZG, An XS.
    Biochem Biophys Res Commun; 2018 Apr 06; 498(3):416-423. PubMed ID: 29454967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.